| Literature DB >> 30102950 |
Anthony P Berger1, Bradley A Ford2, Zoe Brown-Joel3, Bridget E Shields4, Misha Rosenbach5, Karolyn A Wanat6.
Abstract
As discussed in the first article in this continuing medical education series, angioinvasive fungal infections pose a significant risk to immunocompromised and immunocompetent patients alike, with a potential for severe morbidity and high mortality. The first article in this series focused on the epidemiology and clinical presentation of these infections; this article discusses the diagnosis, management, and potential complications of these infections. The mainstay diagnostic tests (positive tissue culture with histologic confirmation) are often supplemented with serum biomarker assays and molecular testing (eg, quantitative polymerase chain reaction analysis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry) to ensure proper speciation. When an angioinvasive fungal infection is suspected or diagnosed, further workup for visceral involvement also is essential and may partially depend on the organism. Different fungal organisms have varied susceptibilities to antifungal agents, and knowledge on optimal treatment regimens is important to avoid the potential complications associated with undertreated or untreated fungal infections.Entities:
Keywords: angioinvasive fungal infections; antifungal therapy; aspergillosis; candidiasis; fusariosis; mucormycetes
Mesh:
Substances:
Year: 2018 PMID: 30102950 DOI: 10.1016/j.jaad.2018.04.058
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 11.527